Results 211 to 220 of about 140,144 (311)

Choosing between Nivo‐AVD and BrECADD: Hodgkin lymphoma's new era

British Journal of Haematology, EarlyView.
Edward R. Scheffer Cliff, Sean McKeague, Michael J. Dickinson   +2 more
wiley   +1 more source

Phenotype‐specific immune profiles and outcomes in childhood autoimmune neutropenia: A 20‐year cohort study

British Journal of Haematology, EarlyView.
Summary Childhood autoimmune neutropenia (AIN) encompasses heterogeneous entities; phenotype‐specific immunological profiles and their relationship to infection outcomes remain incompletely defined. To characterise clinical, immunological and long‐term outcomes across distinct phenotypes of childhood AIN.
Ioanna Saougou, Chrysoula Kosmeri, Nikolaos Chaliasos, Irene Mavroudi, Charalampos Pontikoglou, Alexandros Makis   +5 more
wiley   +1 more source

Fosfomycin versus ciprofloxacin for febrile neutropenia prophylaxis in high-risk haematological patients (FOVOCIP): a phase 3, open-label, multicentre, randomised, non-inferiority trial. [PDF]

Lancet Reg Health Eur
Moreno AF, López de Ugarriza P, González Huerta AJ, Pascual BB, Cáceres S, Blanco LS, Calabuig ML, Zarzuela MP, Rodríguez-Veiga R, Montesinos P, Fernández Verdugo AM, González-Barbera EM, Izquierdo M, Medel-Plaza M, Colomina J, Olave MT, Humala K, López L, Labrador J, Seral C, Amigo ML, de Toro M, Carrascoso GR, Megías G, Blázquez R, Antuña M, Lumbreras P, Domínguez JF, Bernal T.   +28 more
europepmc   +1 more source

Efficacy and safety of BCMA- or GPRC5D-directed CD3 bispecific antibodies in relapsed/refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials and real-world studies. [PDF]

Front Immunol
Li J, Abulaiti A, Li D, Zhao Y, Wahafu P, Maimaitiming M, Qiu S, Zhang Y, An Y, Wang W, Shi L, Yakufu M, Shu L, Li G, Liu Z.   +14 more
europepmc   +1 more source

Development and analytical validation of a targeted short‐read next generation sequencing‐based pharmacogenetic panel for comprehensive variant detection

British Journal of Pharmacology, EarlyView.
Abstract Background and Purpose Genomic profiling of patients for genetic variants that modify the effect of specific medications has many benefits, including the possibility of avoiding toxicities and ensuring an adequate effect of the medication. Our intention was to develop a comprehensive, high‐quality pharmacogenetic test panel for clinical use ...
Anna Gréen, Nils Johan Fredriksson, Michael Andresen, Jon Jonasson, Malin Lindqvist Appell, Henrik Gréen   +5 more
wiley   +1 more source

Perforated acalculous cholecystitis in a neutropenic patient following chemotherapy: a fatal case report. [PDF]

J Surg Case Rep
Deng YJ.
europepmc   +1 more source

First‐In‐Human Study: Dose Expansion of E7130 in Urothelial Carcinoma and Squamous Cell Carcinoma of the Head and Neck

Cancer Science, EarlyView.
The dose escalation part of the first‐in‐human study of E7130 in patients with advanced solid tumors determined the Recommended Phase 2 Dose of E7130 (480 μg/m2 Q3W). The dose expansion part (presented here) examined safety/preliminary efficacy in patients with squamous cell carcinoma of the head and neck and urothelial carcinoma.
Nobuaki Matsubara, Ken Saijo, Yasushi Shimizu, Susumu Okano, Kenji Nakano, Naoki Nishio, Tomoyuki Otsuka, Hirofumi Kuno, Takuma Miura, Tomoki Kubota, Hiroki Ikezawa, Yuko Umetsu, Ken Ito, Abraham Apfel, Yuanqing Ye, Yoshitaka Honma   +15 more
wiley   +1 more source

Mutational Signature‐Based Biomarker for Phase II Trial of Olaparib Maintenance in Advanced High‐Grade Ovarian Cancer

Cancer Science, EarlyView.
A whole‐exome sequencing–based mutational signature biomarker (MSBM) identified an HRD‐enriched population in advanced ovarian cancer. In a phase II trial, olaparib maintenance suggested clinically meaningful PFS benefit without bevacizumab, supporting MSBM as a complementary HRD assessment approach.
Katsutoshi Oda, Daisuke Shintani, Akira Nishijima, Mayuyo Mori, Kazuyoshi Kato, Shoji Nagao, Noriomi Matsumura, Masahiro Kagabu, Masataka Takenaka, Kosuke Yoshihara, Yosuke Konno, Junzo Hamanishi, Sho Sato, Shiro Takamatsu, Keiko Ueda, Kosuke Kashiwabara, Takashi Aoki, Kunihiro Nishimura, Kenji Tatsuno, Hiroyuki Aburatani, Kosei Hasegawa   +20 more
wiley   +1 more source

Real-world pharmacokinetics of venetoclax in patients with acute myeloid leukemia in Japan. [PDF]

Blood Neoplasia
Kanaya M, Mukai Y, Yoshimoto G, Kobayashi M, Kajikawa S, Suzuki T, Miyashita N, Harada S, Ishio T, Yokoyama E, Izumiyama K, Saito M, Morioka M, Mori A, Matsukawa T, Onozawa M, Moriyama M, Chi S, Doki K, Teshima T, Minami Y, Homma M, Kondo T.   +22 more
europepmc   +1 more source

Analysis of an Age-Structured Model of Chemotherapy-Induced Neutropenia [PDF]

, 2014
Safranek, Lee Joseph
core